{"transactions":[{"id":687873,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":23682,"kind":"person","name":"STERN ADAM K","position":1,"cik":"0001403497","reported_name":"STERN ADAM K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2026-08-13T20:04:03.000Z","date":"2026-07-10","kind":"other","planned":false,"acquired":true,"shares":141462,"price":0.35,"value":49511.7,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"On July 10, 2026, the Registrant issued warrants to purchase 374,330 shares of Common Stock (the \"Solicitation Agent Warrants\") to ThinkEquity LLC in connection with a Solicitation Agreement, dated June 25, 2026. The Solicitation Agent Warrants have terms substantially similar to the New Warrants, including with respect to exercise price, expiration and term. ThinkEquity LLC distributed 141,462 Solicitation Agent Warrants to Mr. Stern."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On July 10, 2026, the Registrant issued warrants to purchase 374,330 shares of Common Stock (the \"Solicitation Agent Warrants\") to ThinkEquity LLC in connection with a Solicitation Agreement, dated June 25, 2026. The Solicitation Agent Warrants have terms substantially similar to the New Warrants, including with respect to exercise price, expiration and term. ThinkEquity LLC distributed 141,462 Solicitation Agent Warrants to Mr. Stern."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On July 10, 2026, the Registrant issued warrants to purchase 374,330 shares of Common Stock (the \"Solicitation Agent Warrants\") to ThinkEquity LLC in connection with a Solicitation Agreement, dated June 25, 2026. The Solicitation Agent Warrants have terms substantially similar to the New Warrants, including with respect to exercise price, expiration and term. ThinkEquity LLC distributed 141,462 Solicitation Agent Warrants to Mr. Stern."}],"balance_after":141462,"derivative":{"exercise_price":0.35,"underlying":"Common Stock, par value $0.0001 per share","underlying_shares":141462},"source":{"system":"sec-edgar","filing":"0000921895-26-002109","document":"form413617016ste_08132026.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1403497/000092189526002109/form413617016ste_08132026.xml","form_type":"4"}},{"id":687872,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":23682,"kind":"person","name":"STERN ADAM K","position":1,"cik":"0001403497","reported_name":"STERN ADAM K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2026-08-13T20:04:03.000Z","date":"2026-07-10","kind":"grant","planned":false,"acquired":true,"shares":344710,"price":0.35,"value":120648.5,"ownership":{"direct":false,"nature":"Through A.K.S Family Partners LP"},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the \"New Warrants\"). The Registrant is required to obtain stockholder approval (\"Inducement Stockholder Approval\") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the \"New Warrants\"). The Registrant is required to obtain stockholder approval (\"Inducement Stockholder Approval\") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the \"New Warrants\"). The Registrant is required to obtain stockholder approval (\"Inducement Stockholder Approval\") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"On June 10, 2026, Sanitam Parnters LLC (\"Sanitam\") distributed its holdings in the Registrant's preferred stock and warrants to its members. A.K.S. Family Partners LP received a portion of such distribution. As such Sanitam no longer beneficially owns any securities of the Registrant."}],"balance_after":344710,"derivative":{"exercise_price":0.35,"underlying":"Common Stock, par value $0.0001 per share","underlying_shares":344710},"source":{"system":"sec-edgar","filing":"0000921895-26-002109","document":"form413617016ste_08132026.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1403497/000092189526002109/form413617016ste_08132026.xml","form_type":"4"}},{"id":687871,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":23682,"kind":"person","name":"STERN ADAM K","position":1,"cik":"0001403497","reported_name":"STERN ADAM K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2026-08-13T20:04:03.000Z","date":"2026-07-10","kind":"other","planned":false,"acquired":false,"shares":344710,"price":0.35,"value":120648.5,"ownership":{"direct":false,"nature":"Through A.K.S Family Partners LP"},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the \"New Warrants\"). The Registrant is required to obtain stockholder approval (\"Inducement Stockholder Approval\") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"On June 10, 2026, Sanitam Parnters LLC (\"Sanitam\") distributed its holdings in the Registrant's preferred stock and warrants to its members. A.K.S. Family Partners LP received a portion of such distribution. As such Sanitam no longer beneficially owns any securities of the Registrant."}],"balance_after":0,"derivative":{"exercise_price":0.35,"exercise_date":"2025-04-08","expiration_date":"2030-04-08","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":344710},"source":{"system":"sec-edgar","filing":"0000921895-26-002109","document":"form413617016ste_08132026.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1403497/000092189526002109/form413617016ste_08132026.xml","form_type":"4"}},{"id":687870,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":23682,"kind":"person","name":"STERN ADAM K","position":1,"cik":"0001403497","reported_name":"STERN ADAM K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2026-08-13T20:04:03.000Z","date":"2026-07-10","kind":"grant","planned":false,"acquired":true,"shares":630335,"price":0.35,"value":220617.25,"ownership":{"direct":false,"nature":"Through SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern"},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the \"New Warrants\"). The Registrant is required to obtain stockholder approval (\"Inducement Stockholder Approval\") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the \"New Warrants\"). The Registrant is required to obtain stockholder approval (\"Inducement Stockholder Approval\") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the \"New Warrants\"). The Registrant is required to obtain stockholder approval (\"Inducement Stockholder Approval\") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement."}],"balance_after":630335,"derivative":{"exercise_price":0.35,"underlying":"Common Stock, par value $0.0001 per share","underlying_shares":630335},"source":{"system":"sec-edgar","filing":"0000921895-26-002109","document":"form413617016ste_08132026.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1403497/000092189526002109/form413617016ste_08132026.xml","form_type":"4"}},{"id":687869,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":23682,"kind":"person","name":"STERN ADAM K","position":1,"cik":"0001403497","reported_name":"STERN ADAM K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2026-08-13T20:04:03.000Z","date":"2026-07-10","kind":"other","planned":false,"acquired":false,"shares":630335,"price":0.35,"value":220617.25,"ownership":{"direct":false,"nature":"Through SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern"},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the \"New Warrants\"). The Registrant is required to obtain stockholder approval (\"Inducement Stockholder Approval\") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement."}],"balance_after":0,"derivative":{"exercise_price":0.35,"exercise_date":"2025-04-08","expiration_date":"2030-04-08","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":630335},"source":{"system":"sec-edgar","filing":"0000921895-26-002109","document":"form413617016ste_08132026.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1403497/000092189526002109/form413617016ste_08132026.xml","form_type":"4"}},{"id":687868,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":23682,"kind":"person","name":"STERN ADAM K","position":1,"cik":"0001403497","reported_name":"STERN ADAM K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2026-08-13T20:04:03.000Z","date":"2025-10-31","kind":"other","planned":false,"acquired":false,"shares":92100,"price":0.6446,"value":59367.66,"ownership":{"direct":false,"nature":"Through SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement."}],"balance_after":630335,"derivative":{"exercise_price":0.6446,"exercise_date":"2025-04-08","expiration_date":"2030-04-08","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":92100},"source":{"system":"sec-edgar","filing":"0000921895-26-002109","document":"form413617016ste_08132026.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1403497/000092189526002109/form413617016ste_08132026.xml","form_type":"4"}},{"id":687867,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":23682,"kind":"person","name":"STERN ADAM K","position":1,"cik":"0001403497","reported_name":"STERN ADAM K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2026-08-13T20:04:03.000Z","date":"2025-10-16","kind":"other","planned":false,"acquired":true,"shares":265,"price":0.586,"value":155.29,"ownership":{"direct":false,"nature":"Through SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern"},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series C Convertible Preferred Stock of the Registrant is perpetual and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement."}],"balance_after":265,"derivative":{"exercise_price":0.586,"exercise_date":"2025-04-04","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":452218},"source":{"system":"sec-edgar","filing":"0000921895-26-002109","document":"form413617016ste_08132026.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1403497/000092189526002109/form413617016ste_08132026.xml","form_type":"4"}},{"id":687866,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":23682,"kind":"person","name":"STERN ADAM K","position":1,"cik":"0001403497","reported_name":"STERN ADAM K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2026-08-13T20:04:03.000Z","date":"2025-10-16","kind":"other","planned":false,"acquired":true,"shares":800000,"price":0.6446,"value":515680.0,"ownership":{"direct":false,"nature":"Through SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement."}],"balance_after":800000,"derivative":{"exercise_price":0.6446,"exercise_date":"2025-04-08","expiration_date":"2030-04-08","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":800000},"source":{"system":"sec-edgar","filing":"0000921895-26-002109","document":"form413617016ste_08132026.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1403497/000092189526002109/form413617016ste_08132026.xml","form_type":"4"}},{"id":687865,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":23682,"kind":"person","name":"STERN ADAM K","position":1,"cik":"0001403497","reported_name":"STERN ADAM K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2026-08-13T20:04:03.000Z","date":"2026-07-10","kind":"other","planned":false,"acquired":true,"shares":630335,"price":0.35,"value":220617.25,"ownership":{"direct":false,"nature":"Through SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern"},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the \"New Warrants\"). The Registrant is required to obtain stockholder approval (\"Inducement Stockholder Approval\") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the \"New Warrants\"). The Registrant is required to obtain stockholder approval (\"Inducement Stockholder Approval\") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received."}],"balance_after":743785,"source":{"system":"sec-edgar","filing":"0000921895-26-002109","document":"form413617016ste_08132026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1403497/000092189526002109/form413617016ste_08132026.xml","form_type":"4"}},{"id":687864,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":23682,"kind":"person","name":"STERN ADAM K","position":1,"cik":"0001403497","reported_name":"STERN ADAM K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2026-08-13T20:04:03.000Z","date":"2026-07-10","kind":"other","planned":false,"acquired":true,"shares":344710,"price":0.35,"value":120648.5,"ownership":{"direct":false,"nature":"Through A.K.S Family Partners LP"},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the \"New Warrants\"). The Registrant is required to obtain stockholder approval (\"Inducement Stockholder Approval\") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the \"New Warrants\"). The Registrant is required to obtain stockholder approval (\"Inducement Stockholder Approval\") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received."}],"balance_after":416900,"source":{"system":"sec-edgar","filing":"0000921895-26-002109","document":"form413617016ste_08132026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1403497/000092189526002109/form413617016ste_08132026.xml","form_type":"4"}},{"id":687863,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":23682,"kind":"person","name":"STERN ADAM K","position":1,"cik":"0001403497","reported_name":"STERN ADAM K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2026-08-13T20:04:03.000Z","date":"2025-10-31","kind":"other","planned":false,"acquired":true,"shares":92100,"price":0.6446,"value":59367.66,"ownership":{"direct":false,"nature":"Through SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On October 16, 2025, SternAegis Ventures, LLC Defined Benefit Plan for the Benefit of Adam K Stern received 800,000 Warrants to purchase Common Stock and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 10, 2026, the Registrant entered into inducement offer letter agreements with certain Reporting Persons, pursuant to which such Reporting Persons agreed to exercise for cash all of their outstanding warrants at the current exercise price of $0.35 per share in consideration for the Registrant's agreement to issue, in a private placement, new unregistered common stock purchase warrants (the \"New Warrants\"). The Registrant is required to obtain stockholder approval (\"Inducement Stockholder Approval\") for the issuance of the shares of common stock underlying the New Warrants. The New Warrants will be exercisable beginning on the date Inducement Stockholder Approval is received at an exercise price of $0.35 per share and will expire on the five-year anniversary of the date Inducement Stockholder Approval is received."}],"balance_after":113450,"source":{"system":"sec-edgar","filing":"0000921895-26-002109","document":"form413617016ste_08132026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1403497/000092189526002109/form413617016ste_08132026.xml","form_type":"4"}},{"id":688229,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":23756,"kind":"organization","name":"Sanitam Partners LLC","position":1,"cik":"0002056830","reported_name":"Sanitam Partners LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2026-08-13T20:01:59.000Z","date":"2026-06-10","kind":"other","planned":false,"acquired":false,"shares":4798636,"price":0.6446,"value":3093200.7656,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 10, 2026, Sanitam Parnters LLC (\"Sanitam\") distributed its holdings in the Registrant's preferred stock and warrants to its members. As such Sanitam no longer beneficially owns any securities of the Registrant."}],"balance_after":0,"derivative":{"exercise_price":0.6446,"exercise_date":"2025-04-08","expiration_date":"2030-04-08","underlying":"Common Stock","underlying_shares":4798636},"source":{"system":"sec-edgar","filing":"0000921895-26-002105","document":"form413617016san_08132026.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2056830/000092189526002105/form413617016san_08132026.xml","form_type":"4"}},{"id":688228,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":23756,"kind":"organization","name":"Sanitam Partners LLC","position":1,"cik":"0002056830","reported_name":"Sanitam Partners LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2026-08-13T20:01:59.000Z","date":"2026-06-10","kind":"other","planned":false,"acquired":false,"shares":1406,"price":0.586,"value":823.916,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 10, 2026, Sanitam Parnters LLC (\"Sanitam\") distributed its holdings in the Registrant's preferred stock and warrants to its members. As such Sanitam no longer beneficially owns any securities of the Registrant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series C Convertible Preferred Stock of the Registrant is perpetual and has no expiration date."}],"balance_after":0,"derivative":{"exercise_price":0.586,"exercise_date":"2025-04-04","underlying":"Common Stock","underlying_shares":2399318},"source":{"system":"sec-edgar","filing":"0000921895-26-002105","document":"form413617016san_08132026.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2056830/000092189526002105/form413617016san_08132026.xml","form_type":"4"}},{"id":1161032,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":42772,"kind":"person","name":"D An Evelyn","position":1,"cik":"0001325168","reported_name":"D An Evelyn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to Buy)","published_at":"2025-05-02T21:19:47.000Z","date":"2025-04-30","kind":"grant","planned":false,"acquired":true,"shares":11600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made subject to the approval of, and in accordance with the terms of, the Issuer's 2025 Equity Incentive Plan (the \"2025 Plan\"), which will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025. 100% of the options vest, subject to stockholder approval of the 2025 Plan, on April 30, 2026."}],"balance_after":11600,"derivative":{"exercise_price":0.59,"expiration_date":"2035-04-30","underlying":"Common Stock","underlying_shares":11600},"source":{"system":"sec-edgar","filing":"0001641172-25-008423","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325168/000164117225008423/ownership.xml","form_type":"4"}},{"id":1160755,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":64216,"kind":"person","name":"Jabbour Jerome D","position":1,"cik":"0001698838","reported_name":"Jabbour Jerome D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to Buy)","published_at":"2025-05-02T21:19:46.000Z","date":"2025-04-30","kind":"grant","planned":false,"acquired":true,"shares":70100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made subject to the approval of, and in accordance with the terms of, the Issuer's 2025 Equity Incentive Plan (the \"2025 Plan\"), which will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025. The options vest, subject to stockholder approval of the 2025 Plan, as to 25% of the shares on April 30, 2026 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing April 30, 2026."}],"balance_after":70100,"derivative":{"exercise_price":0.59,"expiration_date":"2035-04-30","underlying":"Common Stock","underlying_shares":70100},"source":{"system":"sec-edgar","filing":"0001641172-25-008424","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582554/000164117225008424/ownership.xml","form_type":"4"}},{"id":1160853,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":69511,"kind":"person","name":"NEUGEBOREN EDWARD","position":1,"cik":"0001320873","reported_name":"NEUGEBOREN EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to Buy)","published_at":"2025-05-02T17:19:50.000Z","date":"2025-04-30","kind":"grant","planned":false,"acquired":true,"shares":11600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made subject to the approval of, and in accordance with the terms of, the Issuer's 2025 Equity Incentive Plan (the \"2025 Plan\"), which will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025. 100% of the options vest, subject to stockholder approval of the 2025 Plan, on April 30, 2026."}],"balance_after":11600,"derivative":{"exercise_price":0.59,"expiration_date":"2035-04-30","underlying":"Common Stock","underlying_shares":11600},"source":{"system":"sec-edgar","filing":"0001641172-25-008426","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1320873/000164117225008426/ownership.xml","form_type":"4"}},{"id":1160827,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":80198,"kind":"person","name":"Smith Robin L","position":1,"cik":"0001365035","reported_name":"Smith Robin L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to Buy)","published_at":"2025-05-02T17:19:48.000Z","date":"2025-04-30","kind":"grant","planned":false,"acquired":true,"shares":11600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made subject to the approval of, and in accordance with the terms of, the Issuer's 2025 Equity Incentive Plan (the \"2025 Plan\"), which will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025. 100% of the options vest, subject to stockholder approval of the 2025 Plan, on April 30, 2026."}],"balance_after":11600,"derivative":{"exercise_price":0.59,"expiration_date":"2035-04-30","underlying":"Common Stock","underlying_shares":11600},"source":{"system":"sec-edgar","filing":"0001641172-25-008427","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365035/000164117225008427/ownership.xml","form_type":"4"}},{"id":1160777,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":68503,"kind":"person","name":"Murphy Keith","position":1,"cik":"0001536583","reported_name":"Murphy Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to Buy)","published_at":"2025-05-02T17:19:45.000Z","date":"2025-04-30","kind":"grant","planned":false,"acquired":true,"shares":11600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made subject to the approval of, and in accordance with the terms of, the Issuer's 2025 Equity Incentive Plan (the \"2025 Plan\"), which will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025. 100% of the options vest, subject to stockholder approval of the 2025 Plan, on April 30, 2026."}],"balance_after":11600,"derivative":{"exercise_price":0.59,"expiration_date":"2035-04-30","underlying":"Common Stock","underlying_shares":11600},"source":{"system":"sec-edgar","filing":"0001641172-25-008425","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536583/000164117225008425/ownership.xml","form_type":"4"}},{"id":1174239,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":23756,"kind":"organization","name":"Sanitam Partners LLC","position":1,"cik":"0002056830","reported_name":"Sanitam Partners LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2025-04-10T20:45:03.000Z","date":"2025-04-08","kind":"purchase","planned":false,"acquired":true,"shares":2399318,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Securities Purchase Agreement, dated February 13, 2025, Sanitam purchased an aggregate of 1,406 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.0001 per share (the \"Preferred Stock\") with a stated value of $1,000 per share of Preferred Stock, and 4,798,636 Warrants for gross proceeds of $1,406,000.00. The Preferred Stock and Warrants were sold in two tranches with each tranche consisting of 703 shares of Preferred Stock and 2,399,318 Warrants."}],"balance_after":4798636,"derivative":{"exercise_price":0.6446,"exercise_date":"2025-04-08","expiration_date":"2030-04-08","underlying":"Common Stock","underlying_shares":2399318},"source":{"system":"sec-edgar","filing":"0001477932-25-002594","document":"form4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2056830/000147793225002594/form4a.xml","form_type":"4/A","original_submission_date":"2025-02-28"}},{"id":1174238,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":23756,"kind":"organization","name":"Sanitam Partners LLC","position":1,"cik":"0002056830","reported_name":"Sanitam Partners LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2025-04-10T20:45:03.000Z","date":"2025-04-08","kind":"purchase","planned":false,"acquired":true,"shares":703,"price":1000,"value":703000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Securities Purchase Agreement, dated February 13, 2025, Sanitam purchased an aggregate of 1,406 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.0001 per share (the \"Preferred Stock\") with a stated value of $1,000 per share of Preferred Stock, and 4,798,636 Warrants for gross proceeds of $1,406,000.00. The Preferred Stock and Warrants were sold in two tranches with each tranche consisting of 703 shares of Preferred Stock and 2,399,318 Warrants."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"N/A"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Each holder of Preferred Stock is entitled to vote on an as-converted to Common Stock basis with a per share voting price of $0.6393, granting Sanitam voting power from the Preferred Strock of up to 30.2% of the outstanding Common Stock. Sanitam's beneficial ownership is subject to a 9.99% limit on the shares of Common Stock issuable upon conversion of the Preferred Stock and a 4.99% limit on the shares of Common Stock issuable upon exercise of the Warrants."}],"balance_after":1406,"derivative":{"exercise_price":0.586,"exercise_date":"2025-04-04","underlying":"Common Stock","underlying_shares":1199659},"source":{"system":"sec-edgar","filing":"0001477932-25-002594","document":"form4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2056830/000147793225002594/form4a.xml","form_type":"4/A","original_submission_date":"2025-02-28"}},{"id":1173987,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":80886,"kind":"person","name":"EIDE ROBERT J","position":1,"cik":"0001181955","reported_name":"EIDE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2025-04-10T13:59:28.000Z","date":"2025-04-08","kind":"purchase","planned":false,"acquired":true,"shares":1679182,"ownership":{"direct":false,"nature":"R. Eide as managing partner for Pembroke"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Securities Purchase Agreement, dated February 13, 2025, Pembroke & Partners (\"Pembroke\") purchased an aggregate of 984 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.0001 per share (the \"Preferred Stock\") with a stated value of $1,000 per share of Preferred Stock, and 3,358,364 Warrants for gross proceeds of $984,000. The Preferred Stock and Warrants were sold in two tranches with each tranche consisting of 492 shares of Preferred Stock and 1,679,182 Warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Eide does not directly own any Preferred Stock or Warrants, however, as the sole manager of Pembroke, Mr. Eide may be deemed to beneficially own securities of the Issuer beneficially owned by Pembroke and share Pembroke's voting power."}],"balance_after":3358364,"derivative":{"exercise_price":0.6446,"exercise_date":"2025-04-08","expiration_date":"2030-04-08","underlying":"Common Stock","underlying_shares":1679182},"source":{"system":"sec-edgar","filing":"0001477932-25-002583","document":"form4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1181955/000147793225002583/form4a.xml","form_type":"4/A","original_submission_date":"2025-03-07"}},{"id":1173986,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":80886,"kind":"person","name":"EIDE ROBERT J","position":1,"cik":"0001181955","reported_name":"EIDE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2025-04-10T13:59:28.000Z","date":"2025-04-08","kind":"purchase","planned":false,"acquired":true,"shares":492,"price":1000,"value":492000.0,"ownership":{"direct":false,"nature":"R. Eide as managing partner for Pembroke"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Securities Purchase Agreement, dated February 13, 2025, Pembroke & Partners (\"Pembroke\") purchased an aggregate of 984 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.0001 per share (the \"Preferred Stock\") with a stated value of $1,000 per share of Preferred Stock, and 3,358,364 Warrants for gross proceeds of $984,000. The Preferred Stock and Warrants were sold in two tranches with each tranche consisting of 492 shares of Preferred Stock and 1,679,182 Warrants."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"N/A"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Each holder of Preferred Stock is entitled to vote on an as-converted to Common Stock basis with a per share voting price of $0.6393, granting Pembroke voting power of up to 23% of the outstanding Common Stock based on their 984 shares of Preferred Stock. Pembroke's beneficial ownership is subject to a 9.99% limit on the shares of Common Stock issuable upon conversion of the Preferred Stock and a 4.99% limit on the shares of Common Stock issuable upon exercise of the Warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Eide does not directly own any Preferred Stock or Warrants, however, as the sole manager of Pembroke, Mr. Eide may be deemed to beneficially own securities of the Issuer beneficially owned by Pembroke and share Pembroke's voting power."}],"balance_after":984,"derivative":{"exercise_price":0.586,"exercise_date":"2025-04-04","underlying":"Common Stock","underlying_shares":839591},"source":{"system":"sec-edgar","filing":"0001477932-25-002583","document":"form4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1181955/000147793225002583/form4a.xml","form_type":"4/A","original_submission_date":"2025-03-07"}},{"id":1174244,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":80893,"kind":"organization","name":"Pembroke & Partners LLC","position":1,"cik":"0002056785","reported_name":"Pembroke & Partners LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2025-04-10T13:54:22.000Z","date":"2025-04-08","kind":"purchase","planned":false,"acquired":true,"shares":1679182,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Securities Purchase Agreement, dated February 13, 2025, Pembroke purchased an aggregate of 984 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.0001 per share (the \"Preferred Stock\") with a stated value of $1,000 per share of Preferred Stock, and 3,358,364 Warrants for gross proceeds of $984,000. The Preferred Stock and Warrants were sold in two tranches with each tranche consisting of 492 shares of Preferred Stock and 1,679,182 Warrants."}],"balance_after":3358364,"derivative":{"exercise_price":0.6446,"exercise_date":"2025-04-08","expiration_date":"2030-04-08","underlying":"Common Stock","underlying_shares":1679182},"source":{"system":"sec-edgar","filing":"0001477932-25-002580","document":"form4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2056785/000147793225002580/form4a.xml","form_type":"4/A","original_submission_date":"2025-02-25"}},{"id":1174243,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":80893,"kind":"organization","name":"Pembroke & Partners LLC","position":1,"cik":"0002056785","reported_name":"Pembroke & Partners LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2025-04-10T13:54:22.000Z","date":"2025-04-08","kind":"purchase","planned":false,"acquired":true,"shares":492,"price":1000,"value":492000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Securities Purchase Agreement, dated February 13, 2025, Pembroke purchased an aggregate of 984 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.0001 per share (the \"Preferred Stock\") with a stated value of $1,000 per share of Preferred Stock, and 3,358,364 Warrants for gross proceeds of $984,000. The Preferred Stock and Warrants were sold in two tranches with each tranche consisting of 492 shares of Preferred Stock and 1,679,182 Warrants."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"N/A"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Each holder of Preferred Stock is entitled to vote on an as-converted to Common Stock basis with a per share voting price of $0.6393, granting Pembroke voting power based on the Preferred Stock of up to 23% of the outstanding Common Stock. Pembroke's beneficial ownership is subject to a 9.99% limit on the shares of Common Stock issuable upon conversion of the Preferred Stock and a 4.99% limit on the shares of Common Stock issuable upon exercise of the Warrants."}],"balance_after":984,"derivative":{"exercise_price":0.586,"exercise_date":"2025-04-04","underlying":"Common Stock","underlying_shares":839591},"source":{"system":"sec-edgar","filing":"0001477932-25-002580","document":"form4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2056785/000147793225002580/form4a.xml","form_type":"4/A","original_submission_date":"2025-02-25"}},{"id":1708768,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":96125,"kind":"person","name":"Matkovits Theresa","position":1,"cik":"0001745393","reported_name":"Matkovits Theresa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2023-12-16T02:46:31.000Z","date":"2023-12-15","kind":"grant","planned":false,"acquired":true,"shares":1300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 15, 2024 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2024."}],"balance_after":1300000,"derivative":{"exercise_price":0.247,"expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":1300000},"source":{"system":"sec-edgar","filing":"0001493152-23-045167","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582554/000149315223045167/ownership.xml","form_type":"4"}},{"id":1708767,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":96124,"kind":"person","name":"Kucinski Keith A","position":1,"cik":"0001763405","reported_name":"Kucinski Keith A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2023-12-16T02:46:25.000Z","date":"2023-12-15","kind":"grant","planned":false,"acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 15, 2024 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2024."}],"balance_after":1000000,"derivative":{"exercise_price":0.247,"expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001493152-23-045171","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582554/000149315223045171/ownership.xml","form_type":"4"}},{"id":1708766,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":96123,"kind":"person","name":"Liu Hui","position":1,"cik":"0001834660","reported_name":"Liu Hui","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2023-12-16T02:46:20.000Z","date":"2023-12-15","kind":"grant","planned":false,"acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 15, 2024 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2024."}],"balance_after":1000000,"derivative":{"exercise_price":0.247,"expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001493152-23-045172","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582554/000149315223045172/ownership.xml","form_type":"4"}},{"id":1708765,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":64216,"kind":"person","name":"Jabbour Jerome D","position":1,"cik":"0001698838","reported_name":"Jabbour Jerome D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to Buy)","published_at":"2023-12-16T02:46:16.000Z","date":"2023-12-15","kind":"grant","planned":false,"acquired":true,"shares":3500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 15, 2024 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2024."}],"balance_after":3500000,"derivative":{"exercise_price":0.247,"expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":3500000},"source":{"system":"sec-edgar","filing":"0001493152-23-045170","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582554/000149315223045170/ownership.xml","form_type":"4"}},{"id":1708764,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":23996,"kind":"person","name":"Ferguson James J. III","position":1,"cik":"0001769041","reported_name":"Ferguson James J. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2023-12-16T02:46:12.000Z","date":"2023-12-15","kind":"grant","planned":false,"acquired":true,"shares":1200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 15, 2024 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2024."}],"balance_after":1200000,"derivative":{"exercise_price":0.247,"expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":1200000},"source":{"system":"sec-edgar","filing":"0001493152-23-045168","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582554/000149315223045168/ownership.xml","form_type":"4"}},{"id":1709583,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":96135,"kind":"person","name":"Hoover Thomas","position":1,"cik":"0001898716","reported_name":"Hoover Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2023-12-15T21:46:29.000Z","date":"2023-12-15","kind":"grant","planned":false,"acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 15, 2024 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2024."}],"balance_after":1000000,"derivative":{"exercise_price":0.247,"expiration_date":"2033-12-15","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001493152-23-045169","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898716/000149315223045169/ownership.xml","form_type":"4"}},{"id":1749387,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":73641,"kind":"person","name":"Corzo Kathryn Penkus","position":1,"cik":"0001884123","reported_name":"Corzo Kathryn Penkus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-11-03T20:49:55.000Z","date":"2023-11-01","kind":"grant","planned":false,"acquired":true,"shares":437244,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the \"2013 Plan\"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan."}],"balance_after":437244,"derivative":{"exercise_price":0.2088,"expiration_date":"2033-11-01","underlying":"Common Stock","underlying_shares":437244},"source":{"system":"sec-edgar","filing":"0001493152-23-039338","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582554/000149315223039338/ownership.xml","form_type":"4"}},{"id":1749493,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":35021,"kind":"person","name":"CONRAD HERBERT J","position":1,"cik":"0001218815","reported_name":"CONRAD HERBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-11-03T20:49:48.000Z","date":"2023-11-01","kind":"grant","planned":false,"acquired":true,"shares":437244,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the \"2013 Plan\"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan."}],"balance_after":437244,"derivative":{"exercise_price":0.2088,"expiration_date":"2033-11-01","underlying":"Common Stock","underlying_shares":437244},"source":{"system":"sec-edgar","filing":"0001493152-23-039336","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1218815/000149315223039336/ownership.xml","form_type":"4"}},{"id":1749743,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":66775,"kind":"person","name":"Ende Eric J","position":1,"cik":"0001494386","reported_name":"Ende Eric J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-11-03T16:49:58.000Z","date":"2023-11-01","kind":"grant","planned":false,"acquired":true,"shares":437244,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the \"2013 Plan\"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan."}],"balance_after":437244,"derivative":{"exercise_price":0.2088,"expiration_date":"2033-11-01","underlying":"Common Stock","underlying_shares":437244},"source":{"system":"sec-edgar","filing":"0001493152-23-039335","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494386/000149315223039335/ownership.xml","form_type":"4"}},{"id":1749500,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":108595,"kind":"person","name":"WIKLER MATTHEW","position":1,"cik":"0001195414","reported_name":"WIKLER MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-11-03T16:49:51.000Z","date":"2023-11-01","kind":"grant","planned":false,"acquired":true,"shares":437244,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the \"2013 Plan\"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan."}],"balance_after":437244,"derivative":{"exercise_price":0.2088,"expiration_date":"2033-11-01","underlying":"Common Stock","underlying_shares":437244},"source":{"system":"sec-edgar","filing":"0001493152-23-039339","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1195414/000149315223039339/ownership.xml","form_type":"4"}},{"id":1749433,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":108594,"kind":"person","name":"Scibetta James S","position":1,"cik":"0001383242","reported_name":"Scibetta James S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-11-03T16:49:45.000Z","date":"2023-11-01","kind":"grant","planned":false,"acquired":true,"shares":437244,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the \"2013 Plan\"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan."}],"balance_after":437244,"derivative":{"exercise_price":0.2088,"expiration_date":"2033-11-01","underlying":"Common Stock","underlying_shares":437244},"source":{"system":"sec-edgar","filing":"0001493152-23-039337","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383242/000149315223039337/ownership.xml","form_type":"4"}},{"id":1749485,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":71585,"kind":"person","name":"Giordano Natasha","position":1,"cik":"0001315585","reported_name":"Giordano Natasha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-11-03T16:49:41.000Z","date":"2023-11-01","kind":"grant","planned":false,"acquired":true,"shares":437244,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the \"2013 Plan\"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan."}],"balance_after":437244,"derivative":{"exercise_price":0.2088,"expiration_date":"2033-11-01","underlying":"Common Stock","underlying_shares":437244},"source":{"system":"sec-edgar","filing":"0001493152-23-039340","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1315585/000149315223039340/ownership.xml","form_type":"4"}},{"id":2077380,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":96125,"kind":"person","name":"Matkovits Theresa","position":1,"cik":"0001745393","reported_name":"Matkovits Theresa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2022-12-22T16:24:50.000Z","date":"2022-12-20","kind":"grant","acquired":true,"shares":625000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 20, 2023 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2023."}],"balance_after":625000,"derivative":{"exercise_price":0.53,"expiration_date":"2032-12-20","underlying":"Common Stock","underlying_shares":625000},"source":{"system":"sec-edgar","filing":"0001493152-22-036243","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582554/000149315222036243/ownership.xml","form_type":"4"}},{"id":2077377,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":96123,"kind":"person","name":"Liu Hui","position":1,"cik":"0001834660","reported_name":"Liu Hui","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2022-12-22T16:23:45.000Z","date":"2022-12-20","kind":"grant","acquired":true,"shares":625000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 20, 2023 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2023."}],"balance_after":625000,"derivative":{"exercise_price":0.53,"expiration_date":"2032-12-20","underlying":"Common Stock","underlying_shares":625000},"source":{"system":"sec-edgar","filing":"0001493152-22-036240","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582554/000149315222036240/ownership.xml","form_type":"4"}},{"id":2077376,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":96124,"kind":"person","name":"Kucinski Keith A","position":1,"cik":"0001763405","reported_name":"Kucinski Keith A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2022-12-22T16:22:03.000Z","date":"2022-12-20","kind":"grant","acquired":true,"shares":625000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 20, 2023 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2023."}],"balance_after":625000,"derivative":{"exercise_price":0.53,"expiration_date":"2032-12-20","underlying":"Common Stock","underlying_shares":625000},"source":{"system":"sec-edgar","filing":"0001493152-22-036238","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582554/000149315222036238/ownership.xml","form_type":"4"}},{"id":2077375,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":64216,"kind":"person","name":"Jabbour Jerome D","position":1,"cik":"0001698838","reported_name":"Jabbour Jerome D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to Buy)","published_at":"2022-12-22T16:20:42.000Z","date":"2022-12-20","kind":"grant","acquired":true,"shares":1988300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 20, 2023 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2023."}],"balance_after":1988300,"derivative":{"exercise_price":0.53,"expiration_date":"2032-12-20","underlying":"Common Stock","underlying_shares":1988300},"source":{"system":"sec-edgar","filing":"0001493152-22-036236","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582554/000149315222036236/ownership.xml","form_type":"4"}},{"id":2077374,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":23996,"kind":"person","name":"Ferguson James J. III","position":1,"cik":"0001769041","reported_name":"Ferguson James J. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2022-12-22T16:17:54.000Z","date":"2022-12-20","kind":"grant","acquired":true,"shares":625000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 20, 2023 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2023."}],"balance_after":625000,"derivative":{"exercise_price":0.53,"expiration_date":"2032-12-20","underlying":"Common Stock","underlying_shares":625000},"source":{"system":"sec-edgar","filing":"0001493152-22-036232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582554/000149315222036232/ownership.xml","form_type":"4"}},{"id":2077878,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":96135,"kind":"person","name":"Hoover Thomas","position":1,"cik":"0001898716","reported_name":"Hoover Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2022-12-22T11:19:45.000Z","date":"2022-12-20","kind":"grant","acquired":true,"shares":475000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 20, 2023 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2023."}],"balance_after":475000,"derivative":{"exercise_price":0.53,"expiration_date":"2032-12-20","underlying":"Common Stock","underlying_shares":475000},"source":{"system":"sec-edgar","filing":"0001493152-22-036234","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898716/000149315222036234/ownership.xml","form_type":"4"}},{"id":2114078,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":73641,"kind":"person","name":"Corzo Kathryn Penkus","position":1,"cik":"0001884123","reported_name":"Corzo Kathryn Penkus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2022-11-17T02:36:09.000Z","date":"2022-11-14","kind":"grant","acquired":true,"shares":142657,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the \"2013 Plan\"). The option vests in equal monthly installments over a period of 12 months commencing on November 14, 2022. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan."}],"balance_after":142657,"derivative":{"exercise_price":0.7268,"expiration_date":"2032-11-14","underlying":"Common Stock","underlying_shares":142657},"source":{"system":"sec-edgar","filing":"0001493152-22-032694","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582554/000149315222032694/ownership.xml","form_type":"4"}},{"id":2114314,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":35021,"kind":"person","name":"CONRAD HERBERT J","position":1,"cik":"0001218815","reported_name":"CONRAD HERBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2022-11-17T02:34:37.000Z","date":"2022-11-14","kind":"grant","acquired":true,"shares":142657,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the \"2013 Plan\"). The option vests in equal monthly installments over a period of 12 months commencing on November 14, 2022. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan."}],"balance_after":142657,"derivative":{"exercise_price":0.7268,"expiration_date":"2032-11-14","underlying":"Common Stock","underlying_shares":142657},"source":{"system":"sec-edgar","filing":"0001493152-22-032692","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1218815/000149315222032692/ownership.xml","form_type":"4"}},{"id":2114297,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":71585,"kind":"person","name":"Giordano Natasha","position":1,"cik":"0001315585","reported_name":"Giordano Natasha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2022-11-16T21:36:48.000Z","date":"2022-11-14","kind":"grant","acquired":true,"shares":142657,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the \"2013 Plan\"). The option vests in equal monthly installments over a period of 12 months commencing on November 14, 2022. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan."}],"balance_after":142657,"derivative":{"exercise_price":0.7268,"expiration_date":"2032-11-14","underlying":"Common Stock","underlying_shares":142657},"source":{"system":"sec-edgar","filing":"0001493152-22-032695","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1315585/000149315222032695/ownership.xml","form_type":"4"}},{"id":2114323,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":108595,"kind":"person","name":"WIKLER MATTHEW","position":1,"cik":"0001195414","reported_name":"WIKLER MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2022-11-16T21:33:28.000Z","date":"2022-11-14","kind":"grant","acquired":true,"shares":142657,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the \"2013 Plan\"). The option vests in equal monthly installments over a period of 12 months commencing on November 14, 2022. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan."}],"balance_after":142657,"derivative":{"exercise_price":0.7268,"expiration_date":"2032-11-14","underlying":"Common Stock","underlying_shares":142657},"source":{"system":"sec-edgar","filing":"0001493152-22-032691","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1195414/000149315222032691/ownership.xml","form_type":"4"}},{"id":2114475,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":66775,"kind":"person","name":"Ende Eric J","position":1,"cik":"0001494386","reported_name":"Ende Eric J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2022-11-16T21:33:19.000Z","date":"2022-11-14","kind":"grant","acquired":true,"shares":142657,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the \"2013 Plan\"). The option vests in equal monthly installments over a period of 12 months commencing on November 14, 2022. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan."}],"balance_after":142657,"derivative":{"exercise_price":0.7268,"expiration_date":"2032-11-14","underlying":"Common Stock","underlying_shares":142657},"source":{"system":"sec-edgar","filing":"0001493152-22-032690","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494386/000149315222032690/ownership.xml","form_type":"4"}},{"id":2114208,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":108594,"kind":"person","name":"Scibetta James S","position":1,"cik":"0001383242","reported_name":"Scibetta James S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2022-11-16T21:31:59.000Z","date":"2022-11-14","kind":"grant","acquired":true,"shares":142657,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the \"2013 Plan\"). The option vests in equal monthly installments over a period of 12 months commencing on November 14, 2022. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan."}],"balance_after":142657,"derivative":{"exercise_price":0.7268,"expiration_date":"2032-11-14","underlying":"Common Stock","underlying_shares":142657},"source":{"system":"sec-edgar","filing":"0001493152-22-032688","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383242/000149315222032688/ownership.xml","form_type":"4"}},{"id":2214200,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":35021,"kind":"person","name":"CONRAD HERBERT J","position":1,"cik":"0001218815","reported_name":"CONRAD HERBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2022-07-05T22:00:12.000Z","date":"2022-06-22","kind":"gift","acquired":true,"shares":1358122,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees"},"balance_after":4694566,"source":{"system":"sec-edgar","filing":"0001493152-22-018581","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1218815/000149315222018581/ownership.xml","form_type":"4"}},{"id":2214199,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":35021,"kind":"person","name":"CONRAD HERBERT J","position":1,"cik":"0001218815","reported_name":"CONRAD HERBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2022-07-05T22:00:12.000Z","date":"2022-06-22","kind":"gift","acquired":false,"shares":1358122,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Herbert Conrad 2020 Grantor Retained Annuity Trust (GRAT)"},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001493152-22-018581","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1218815/000149315222018581/ownership.xml","form_type":"4"}},{"id":2214198,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":35021,"kind":"person","name":"CONRAD HERBERT J","position":1,"cik":"0001218815","reported_name":"CONRAD HERBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2022-07-05T22:00:12.000Z","date":"2021-08-04","kind":"gift","acquired":true,"shares":494622,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees"},"balance_after":3336444,"source":{"system":"sec-edgar","filing":"0001493152-22-018581","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1218815/000149315222018581/ownership.xml","form_type":"4"}},{"id":2214197,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":35021,"kind":"person","name":"CONRAD HERBERT J","position":1,"cik":"0001218815","reported_name":"CONRAD HERBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2022-07-05T22:00:12.000Z","date":"2021-08-04","kind":"gift","acquired":false,"shares":494622,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001493152-22-018581","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1218815/000149315222018581/ownership.xml","form_type":"4"}},{"id":2453969,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":108595,"kind":"person","name":"WIKLER MATTHEW","position":1,"cik":"0001195414","reported_name":"WIKLER MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-03T17:45:54.000Z","date":"2021-12-31","kind":"grant","acquired":true,"shares":7859,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 31, 2021, the Reporting Person was issued 7,859 shares of common stock, par value $0.0001 per share, pursuant to the Issuer's Amended and Restated 2013 Equity Compensation Plan. Such shares vest immediately upon grant."}],"balance_after":290472,"source":{"system":"sec-edgar","filing":"0000905718-22-000007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1195414/000090571822000007/ownership.xml","form_type":"4"}},{"id":2471215,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":64216,"kind":"person","name":"Jabbour Jerome D","position":1,"cik":"0001698838","reported_name":"Jabbour Jerome D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to Buy)","published_at":"2021-12-16T02:29:56.000Z","date":"2021-12-14","kind":"grant","acquired":true,"shares":1658100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 14, 2022 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2022."}],"balance_after":1658100,"derivative":{"exercise_price":0.92,"expiration_date":"2031-12-13","underlying":"Common Stock","underlying_shares":1658100},"source":{"system":"sec-edgar","filing":"0000905718-21-001615","document":"matinas_fm4dec142021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582554/000090571821001615/matinas_fm4dec142021.xml","form_type":"4"}},{"id":2471216,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":96124,"kind":"person","name":"Kucinski Keith A","position":1,"cik":"0001763405","reported_name":"Kucinski Keith A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2021-12-16T02:25:54.000Z","date":"2021-12-14","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 14, 2022 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2022."}],"balance_after":500000,"derivative":{"exercise_price":0.92,"expiration_date":"2031-12-13","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000905718-21-001613","document":"matinas_fm4dec142021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582554/000090571821001613/matinas_fm4dec142021.xml","form_type":"4"}},{"id":2471214,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":96123,"kind":"person","name":"Liu Hui","position":1,"cik":"0001834660","reported_name":"Hui Liu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2021-12-16T02:24:19.000Z","date":"2021-12-14","kind":"grant","acquired":true,"shares":275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 14, 2022 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2022."}],"balance_after":275000,"derivative":{"exercise_price":0.92,"expiration_date":"2031-12-13","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0000905718-21-001611","document":"matinas_fm4dec142021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582554/000090571821001611/matinas_fm4dec142021.xml","form_type":"4"}},{"id":2471213,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":96125,"kind":"person","name":"Matkovits Theresa","position":1,"cik":"0001745393","reported_name":"Matkovits Theresa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2021-12-16T02:20:20.000Z","date":"2021-12-14","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 14, 2022 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2022."}],"balance_after":500000,"derivative":{"exercise_price":0.92,"expiration_date":"2031-12-13","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000905718-21-001607","document":"matinas_fm4dec142021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582554/000090571821001607/matinas_fm4dec142021.xml","form_type":"4"}},{"id":2471212,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":23996,"kind":"person","name":"Ferguson James J. III","position":1,"cik":"0001769041","reported_name":"Ferguson James J. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2021-12-16T02:18:42.000Z","date":"2021-12-14","kind":"grant","acquired":true,"shares":587600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 14, 2022 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2022."}],"balance_after":587600,"derivative":{"exercise_price":0.92,"expiration_date":"2031-12-13","underlying":"Common Stock","underlying_shares":587600},"source":{"system":"sec-edgar","filing":"0000905718-21-001605","document":"matinas_fm4dec142021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582554/000090571821001605/matinas_fm4dec142021.xml","form_type":"4"}},{"id":2471386,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":132350,"kind":"person","name":"MANNINO RAPHAEL J","position":1,"cik":"0001196697","reported_name":"MANNINO RAPHAEL J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2021-12-15T21:22:17.000Z","date":"2021-12-14","kind":"grant","acquired":true,"shares":275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 14, 2022 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2022."}],"balance_after":275000,"derivative":{"exercise_price":0.92,"expiration_date":"2031-12-13","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0000905718-21-001609","document":"matinas_fm4dec152021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196697/000090571821001609/matinas_fm4dec152021.xml","form_type":"4"}},{"id":2471943,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":96135,"kind":"person","name":"Hoover Thomas","position":1,"cik":"0001898716","reported_name":"Hoover Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2021-12-15T21:16:51.000Z","date":"2021-12-14","kind":"grant","acquired":true,"shares":850000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 14, 2022 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2022."}],"balance_after":850000,"derivative":{"exercise_price":0.92,"expiration_date":"2031-12-13","underlying":"Common Stock","underlying_shares":850000},"source":{"system":"sec-edgar","filing":"0000905718-21-001603","document":"matinasbio_fm4dec142021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898716/000090571821001603/matinasbio_fm4dec142021.xml","form_type":"4"}},{"id":2528394,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":35021,"kind":"person","name":"CONRAD HERBERT J","position":1,"cik":"0001218815","reported_name":"CONRAD HERBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-11-02T20:17:01.000Z","date":"2021-11-01","kind":"grant","acquired":true,"shares":90882,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the \"2013 Plan\"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2021. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan."}],"balance_after":90882,"derivative":{"exercise_price":1.12,"expiration_date":"2031-11-01","underlying":"Common Stock","underlying_shares":90882},"source":{"system":"sec-edgar","filing":"0001493152-21-026989","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1218815/000149315221026989/ownership.xml","form_type":"4"}},{"id":2528215,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":73641,"kind":"person","name":"Corzo Kathryn Penkus","position":1,"cik":"0001884123","reported_name":"Corzo Kathryn Penkus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-11-02T20:13:49.000Z","date":"2021-11-01","kind":"grant","acquired":true,"shares":181763,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the \"2013 Plan\"). The option vests in equal monthly installments over a period of 36 months commencing on November 30, 2021. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan."}],"balance_after":181763,"derivative":{"exercise_price":1.12,"expiration_date":"2031-11-01","underlying":"Common Stock","underlying_shares":181763},"source":{"system":"sec-edgar","filing":"0001493152-21-026985","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582554/000149315221026985/ownership.xml","form_type":"4"}},{"id":2528381,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":71585,"kind":"person","name":"Giordano Natasha","position":1,"cik":"0001315585","reported_name":"Giordano Natasha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-11-02T16:22:58.000Z","date":"2021-11-01","kind":"grant","acquired":true,"shares":90882,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the \"2013 Plan\"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2021. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan."}],"balance_after":90882,"derivative":{"exercise_price":1.12,"expiration_date":"2031-11-01","underlying":"Common Stock","underlying_shares":90882},"source":{"system":"sec-edgar","filing":"0001493152-21-026993","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1315585/000149315221026993/ownership.xml","form_type":"4"}},{"id":2528409,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":108595,"kind":"person","name":"WIKLER MATTHEW","position":1,"cik":"0001195414","reported_name":"WIKLER MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-11-02T16:21:20.000Z","date":"2021-11-01","kind":"grant","acquired":true,"shares":90882,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the \"2013 Plan\"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2021. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan."}],"balance_after":90882,"derivative":{"exercise_price":1.12,"expiration_date":"2031-11-01","underlying":"Common Stock","underlying_shares":90882},"source":{"system":"sec-edgar","filing":"0001493152-21-026991","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1195414/000149315221026991/ownership.xml","form_type":"4"}},{"id":2528327,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":108594,"kind":"person","name":"Scibetta James S","position":1,"cik":"0001383242","reported_name":"Scibetta James S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-11-02T16:18:31.000Z","date":"2021-11-01","kind":"grant","acquired":true,"shares":90882,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the \"2013 Plan\"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2021. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan."}],"balance_after":90882,"derivative":{"exercise_price":1.12,"expiration_date":"2031-11-01","underlying":"Common Stock","underlying_shares":90882},"source":{"system":"sec-edgar","filing":"0001493152-21-026990","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383242/000149315221026990/ownership.xml","form_type":"4"}},{"id":2528871,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":66775,"kind":"person","name":"Ende Eric J","position":1,"cik":"0001494386","reported_name":"Ende Eric J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-11-02T16:15:51.000Z","date":"2021-11-01","kind":"grant","acquired":true,"shares":90882,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the \"2013 Plan\"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2021. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan."}],"balance_after":90882,"derivative":{"exercise_price":1.12,"expiration_date":"2031-11-01","underlying":"Common Stock","underlying_shares":90882},"source":{"system":"sec-edgar","filing":"0001493152-21-026987","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494386/000149315221026987/ownership.xml","form_type":"4"}},{"id":2554130,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":108595,"kind":"person","name":"WIKLER MATTHEW","position":1,"cik":"0001195414","reported_name":"WIKLER MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-01T18:03:43.000Z","date":"2021-09-30","kind":"grant","acquired":true,"shares":6106,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On September 30, 2021, the Reporting Person was issued 6,106 shares of common stock par value $.0001 per share pursuant to the Issuer's Amended and Restated 2013 Equity Compensation Plan. Such shares vest immediately upon grant."}],"balance_after":282613,"source":{"system":"sec-edgar","filing":"0001493152-21-024397","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1195414/000149315221024397/ownership.xml","form_type":"4"}},{"id":2570537,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":132350,"kind":"person","name":"MANNINO RAPHAEL J","position":1,"cik":"0001196697","reported_name":"MANNINO RAPHAEL J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-09-14T17:30:10.000Z","date":"2021-09-03","kind":"other","acquired":true,"shares":462150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares received pursuant to an amendment to the Agreement and Plan of Merger dated as of January 29, 2015 by an among the Issuer, Saffron Merger Sub, Inc. and Aquarius Biotechnologies Inc."}],"balance_after":1919715,"source":{"system":"sec-edgar","filing":"0001493152-21-022716","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196697/000149315221022716/ownership.xml","form_type":"4"}},{"id":2636874,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":35021,"kind":"person","name":"CONRAD HERBERT J","position":1,"cik":"0001218815","reported_name":"CONRAD HERBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-07-09T21:30:14.000Z","date":"2021-07-07","kind":"gift","acquired":true,"shares":1280917,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees"},"balance_after":2841822,"source":{"system":"sec-edgar","filing":"0001493152-21-016565","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1218815/000149315221016565/ownership.xml","form_type":"4"}},{"id":2636873,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":35021,"kind":"person","name":"CONRAD HERBERT J","position":1,"cik":"0001218815","reported_name":"CONRAD HERBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-07-09T21:30:14.000Z","date":"2021-07-07","kind":"gift","acquired":false,"shares":1280917,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Herbert Conrad 2020 Grantor Retained Annuity Trust (GRAT)"},"balance_after":1358122,"source":{"system":"sec-edgar","filing":"0001493152-21-016565","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1218815/000149315221016565/ownership.xml","form_type":"4"}},{"id":2647337,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":108595,"kind":"person","name":"WIKLER MATTHEW","position":1,"cik":"0001195414","reported_name":"WIKLER MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-01T17:30:19.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":10244,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On June 30, 2021, the Reporting Person was issued 10,244 shares of common stock par value $.0001 per share pursuant to the Issuer's Amended and Restated 2013 Equity Compensation Plan. Such shares vest immediately upon grant."}],"balance_after":276507,"source":{"system":"sec-edgar","filing":"0001493152-21-015878","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1195414/000149315221015878/ownership.xml","form_type":"4"}},{"id":2655540,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":64216,"kind":"person","name":"Jabbour Jerome D","position":1,"cik":"0001698838","reported_name":"Jabbour Jerome D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Series B Preferred Stock","published_at":"2021-06-24T21:49:06.000Z","date":"2021-06-19","kind":"exercise","acquired":false,"shares":15,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the \"Certificate\") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the \"Certificate\") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"exercise_price":0.5,"exercise_date":"2018-06-21","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000905718-21-000830","document":"matinasbio_fm4jun192021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1582554/000090571821000830/matinasbio_fm4jun192021.xml","form_type":"4"}},{"id":2655539,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":64216,"kind":"person","name":"Jabbour Jerome D","position":1,"cik":"0001698838","reported_name":"Jabbour Jerome D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-06-24T21:49:06.000Z","date":"2021-06-19","kind":"exercise","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the \"Certificate\") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date."}],"balance_after":840011,"source":{"system":"sec-edgar","filing":"0000905718-21-000830","document":"matinasbio_fm4jun192021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582554/000090571821000830/matinasbio_fm4jun192021.xml","form_type":"4"}},{"id":2655538,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":64216,"kind":"person","name":"Jabbour Jerome D","position":1,"cik":"0001698838","reported_name":"Jabbour Jerome D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-06-24T21:49:06.000Z","date":"2021-06-19","kind":"other","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Stock dividend, payable to all holders of record of Series B Preferred Stock of 400 shares of Common Stock for each share of Series B Preferred Stock."}],"balance_after":810011,"source":{"system":"sec-edgar","filing":"0000905718-21-000830","document":"matinasbio_fm4jun192021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582554/000090571821000830/matinasbio_fm4jun192021.xml","form_type":"4"}},{"id":2655682,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":35021,"kind":"person","name":"CONRAD HERBERT J","position":1,"cik":"0001218815","reported_name":"CONRAD HERBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-06-24T21:37:54.000Z","date":"2021-06-19","kind":"exercise","acquired":false,"shares":100,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the \"Certificate\") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the \"Certificate\") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"exercise_price":0.5,"exercise_date":"2018-06-21","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000905718-21-000824","document":"matinasbio_fm4jun192021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1218815/000090571821000824/matinasbio_fm4jun192021.xml","form_type":"4"}},{"id":2655681,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":35021,"kind":"person","name":"CONRAD HERBERT J","position":1,"cik":"0001218815","reported_name":"CONRAD HERBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-06-24T21:37:54.000Z","date":"2021-06-19","kind":"exercise","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the \"Certificate\") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date."}],"balance_after":1560905,"source":{"system":"sec-edgar","filing":"0000905718-21-000824","document":"matinasbio_fm4jun192021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1218815/000090571821000824/matinasbio_fm4jun192021.xml","form_type":"4"}},{"id":2655680,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":35021,"kind":"person","name":"CONRAD HERBERT J","position":1,"cik":"0001218815","reported_name":"CONRAD HERBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-06-24T21:37:54.000Z","date":"2021-06-19","kind":"other","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Stock dividend, payable to all holders of record of Series B Preferred Stock of 400 shares of Common Stock for each share of Series B Preferred Stock."}],"balance_after":1360905,"source":{"system":"sec-edgar","filing":"0000905718-21-000824","document":"matinasbio_fm4jun192021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1218815/000090571821000824/matinasbio_fm4jun192021.xml","form_type":"4"}},{"id":2655804,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":66775,"kind":"person","name":"Ende Eric J","position":1,"cik":"0001494386","reported_name":"Ende Eric J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-06-24T17:55:36.000Z","date":"2021-06-19","kind":"exercise","acquired":false,"shares":12,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the \"Certificate\") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the \"Certificate\") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"exercise_price":0.5,"exercise_date":"2018-06-21","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0000905718-21-000832","document":"matinasbio_fm4jun192021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1494386/000090571821000832/matinasbio_fm4jun192021.xml","form_type":"4"}},{"id":2655803,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":66775,"kind":"person","name":"Ende Eric J","position":1,"cik":"0001494386","reported_name":"Ende Eric J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-06-24T17:55:36.000Z","date":"2021-06-19","kind":"exercise","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the \"Certificate\") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date."}],"balance_after":144092,"source":{"system":"sec-edgar","filing":"0000905718-21-000832","document":"matinasbio_fm4jun192021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1494386/000090571821000832/matinasbio_fm4jun192021.xml","form_type":"4"}},{"id":2655802,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":66775,"kind":"person","name":"Ende Eric J","position":1,"cik":"0001494386","reported_name":"Ende Eric J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-06-24T17:55:36.000Z","date":"2021-06-19","kind":"other","acquired":true,"shares":4800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Stock dividend, payable to all holders of record of Series B Preferred Stock of 400 shares of Common Stock for each share of Series B Preferred Stock."}],"balance_after":120092,"source":{"system":"sec-edgar","filing":"0000905718-21-000832","document":"matinasbio_fm4jun192021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494386/000090571821000832/matinasbio_fm4jun192021.xml","form_type":"4"}},{"id":2655612,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":108594,"kind":"person","name":"Scibetta James S","position":1,"cik":"0001383242","reported_name":"Scibetta James S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-06-24T17:46:11.000Z","date":"2021-06-19","kind":"exercise","acquired":false,"shares":12,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the \"Certificate\") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the \"Certificate\") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"exercise_price":0.5,"exercise_date":"2018-06-21","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0000905718-21-000828","document":"matinasbio_fm4jun192021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1383242/000090571821000828/matinasbio_fm4jun192021.xml","form_type":"4"}},{"id":2655611,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":108594,"kind":"person","name":"Scibetta James S","position":1,"cik":"0001383242","reported_name":"Scibetta James S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-06-24T17:46:11.000Z","date":"2021-06-19","kind":"exercise","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the \"Certificate\") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date."}],"balance_after":649958,"source":{"system":"sec-edgar","filing":"0000905718-21-000828","document":"matinasbio_fm4jun192021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1383242/000090571821000828/matinasbio_fm4jun192021.xml","form_type":"4"}},{"id":2655610,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":108594,"kind":"person","name":"Scibetta James S","position":1,"cik":"0001383242","reported_name":"Scibetta James S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-06-24T17:46:11.000Z","date":"2021-06-19","kind":"other","acquired":true,"shares":4800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Stock dividend, payable to all holders of record of Series B Preferred Stock of 400 shares of Common Stock for each share of Series B Preferred Stock."}],"balance_after":625958,"source":{"system":"sec-edgar","filing":"0000905718-21-000828","document":"matinasbio_fm4jun192021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383242/000090571821000828/matinasbio_fm4jun192021.xml","form_type":"4"}},{"id":2655694,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":108595,"kind":"person","name":"WIKLER MATTHEW","position":1,"cik":"0001195414","reported_name":"WIKLER MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-06-24T17:42:15.000Z","date":"2021-06-19","kind":"exercise","acquired":false,"shares":6,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the \"Certificate\") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the \"Certificate\") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"exercise_price":0.5,"exercise_date":"2018-06-21","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000905718-21-000826","document":"matinasbio_fm4jun192021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1195414/000090571821000826/matinasbio_fm4jun192021.xml","form_type":"4"}},{"id":2655693,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":108595,"kind":"person","name":"WIKLER MATTHEW","position":1,"cik":"0001195414","reported_name":"WIKLER MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-06-24T17:42:15.000Z","date":"2021-06-19","kind":"exercise","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the \"Certificate\") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date."}],"balance_after":266263,"source":{"system":"sec-edgar","filing":"0000905718-21-000826","document":"matinasbio_fm4jun192021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1195414/000090571821000826/matinasbio_fm4jun192021.xml","form_type":"4"}},{"id":2655692,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":108595,"kind":"person","name":"WIKLER MATTHEW","position":1,"cik":"0001195414","reported_name":"WIKLER MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-06-24T17:42:15.000Z","date":"2021-06-19","kind":"other","acquired":true,"shares":2400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Stock dividend, payable to all holders of record of Series B Preferred Stock of 400 shares of Common Stock for each share of Series B Preferred Stock."}],"balance_after":254263,"source":{"system":"sec-edgar","filing":"0000905718-21-000826","document":"matinasbio_fm4jun192021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1195414/000090571821000826/matinasbio_fm4jun192021.xml","form_type":"4"}},{"id":2655697,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":132350,"kind":"person","name":"MANNINO RAPHAEL J","position":1,"cik":"0001196697","reported_name":"MANNINO RAPHAEL J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Series B Preferred Stock","published_at":"2021-06-24T17:35:04.000Z","date":"2021-06-19","kind":"exercise","acquired":false,"shares":10,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the \"Certificate\") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the \"Certificate\") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"exercise_price":0.5,"exercise_date":"2018-06-21","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000905718-21-000822","document":"matinasbio_fm4jun192021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1196697/000090571821000822/matinasbio_fm4jun192021.xml","form_type":"4"}},{"id":2655696,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":132350,"kind":"person","name":"MANNINO RAPHAEL J","position":1,"cik":"0001196697","reported_name":"MANNINO RAPHAEL J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-06-24T17:35:04.000Z","date":"2021-06-19","kind":"exercise","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the \"Certificate\") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date."}],"balance_after":1457565,"source":{"system":"sec-edgar","filing":"0000905718-21-000822","document":"matinasbio_fm4jun192021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1196697/000090571821000822/matinasbio_fm4jun192021.xml","form_type":"4"}},{"id":2655695,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":132350,"kind":"person","name":"MANNINO RAPHAEL J","position":1,"cik":"0001196697","reported_name":"MANNINO RAPHAEL J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-06-24T17:35:04.000Z","date":"2021-06-19","kind":"other","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Stock dividend, payable to all holders of record of Series B Preferred Stock of 400 shares of Common Stock for each share of Series B Preferred Stock."}],"balance_after":1437565,"source":{"system":"sec-edgar","filing":"0000905718-21-000822","document":"matinasbio_fm4jun192021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196697/000090571821000822/matinasbio_fm4jun192021.xml","form_type":"4"}},{"id":2698484,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":35021,"kind":"person","name":"CONRAD HERBERT J","position":1,"cik":"0001218815","reported_name":"CONRAD HERBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2021-05-24T21:30:18.000Z","date":"2021-01-13","kind":"gift","acquired":true,"shares":100,"price":1000,"value":100000.0,"ownership":{"direct":false,"nature":"By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Convertible Preferred Stock is convertible into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock are convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Convertible Preferred Stock is convertible into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock are convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date."}],"balance_after":100,"derivative":{"exercise_price":0.5,"exercise_date":"2018-06-21","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001493152-21-012764","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1218815/000149315221012764/ownership.xml","form_type":"4"}},{"id":2698483,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":35021,"kind":"person","name":"CONRAD HERBERT J","position":1,"cik":"0001218815","reported_name":"CONRAD HERBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2021-05-24T21:30:18.000Z","date":"2021-01-13","kind":"gift","acquired":false,"shares":100,"price":1000,"value":100000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Convertible Preferred Stock is convertible into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock are convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Convertible Preferred Stock is convertible into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock are convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date."}],"balance_after":0,"derivative":{"exercise_price":0.5,"exercise_date":"2018-06-21","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001493152-21-012764","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1218815/000149315221012764/ownership.xml","form_type":"4"}},{"id":2698482,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":35021,"kind":"person","name":"CONRAD HERBERT J","position":1,"cik":"0001218815","reported_name":"CONRAD HERBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-05-24T21:30:18.000Z","date":"2021-05-20","kind":"gift","acquired":true,"shares":1145905,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees"},"balance_after":1320905,"source":{"system":"sec-edgar","filing":"0001493152-21-012764","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1218815/000149315221012764/ownership.xml","form_type":"4"}},{"id":2698481,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":35021,"kind":"person","name":"CONRAD HERBERT J","position":1,"cik":"0001218815","reported_name":"CONRAD HERBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-05-24T21:30:18.000Z","date":"2021-05-20","kind":"gift","acquired":false,"shares":1145905,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Herbert Conrad 2019 Grantor Retained Annuity Trust (GRAT)"},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001493152-21-012764","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1218815/000149315221012764/ownership.xml","form_type":"4"}},{"id":2698480,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":35021,"kind":"person","name":"CONRAD HERBERT J","position":1,"cik":"0001218815","reported_name":"CONRAD HERBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-05-24T21:30:18.000Z","date":"2021-01-13","kind":"gift","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees"},"balance_after":175000,"source":{"system":"sec-edgar","filing":"0001493152-21-012764","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1218815/000149315221012764/ownership.xml","form_type":"4"}},{"id":2698479,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":35021,"kind":"person","name":"CONRAD HERBERT J","position":1,"cik":"0001218815","reported_name":"CONRAD HERBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-05-24T21:30:18.000Z","date":"2021-01-13","kind":"gift","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":494622,"source":{"system":"sec-edgar","filing":"0001493152-21-012764","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1218815/000149315221012764/ownership.xml","form_type":"4"}},{"id":2757267,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":108595,"kind":"person","name":"WIKLER MATTHEW","position":1,"cik":"0001195414","reported_name":"WIKLER MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-05T19:25:29.000Z","date":"2021-03-31","kind":"grant","acquired":true,"shares":7560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 31, 2021, the Reporting Person was issued 7,560 shares of common stock par value $.0001 per share pursuant to the Issuer's Amended and Restated 2013 Equity Compensation Plan. Such shares vest immediately upon grant."}],"balance_after":251863,"source":{"system":"sec-edgar","filing":"0000905718-21-000556","document":"wikler_fm4mar312021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1195414/000090571821000556/wikler_fm4mar312021.xml","form_type":"4"}},{"id":2924950,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":96125,"kind":"person","name":"Matkovits Theresa","position":1,"cik":"0001745393","reported_name":"Matkovits Theresa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-01-04T23:30:13.000Z","date":"2021-01-01","kind":"grant","acquired":true,"shares":425000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on January 1, 2022 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on February 1, 2022."}],"balance_after":425000,"derivative":{"exercise_price":1.36,"expiration_date":"2030-12-31","underlying":"Common Stock","underlying_shares":425000},"source":{"system":"sec-edgar","filing":"0001493152-21-000136","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582554/000149315221000136/ownership.xml","form_type":"4"}},{"id":2924949,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":96123,"kind":"person","name":"Liu Hui","position":1,"cik":"0001834660","reported_name":"Hui Liu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-01-04T23:30:12.000Z","date":"2021-01-01","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on January 1, 2022 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on February 1, 2022."}],"balance_after":250000,"derivative":{"exercise_price":1.36,"expiration_date":"2030-12-31","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001493152-21-000134","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582554/000149315221000134/ownership.xml","form_type":"4"}},{"id":2924948,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":64216,"kind":"person","name":"Jabbour Jerome D","position":1,"cik":"0001698838","reported_name":"Jabbour Jerome D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2021-01-04T23:30:10.000Z","date":"2021-01-01","kind":"grant","acquired":true,"shares":1600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on January 1, 2022 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on February 1, 2022."}],"balance_after":1600000,"derivative":{"exercise_price":1.36,"expiration_date":"2030-12-31","underlying":"Common Stock","underlying_shares":1600000},"source":{"system":"sec-edgar","filing":"0001493152-21-000133","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582554/000149315221000133/ownership.xml","form_type":"4"}},{"id":2924947,"issuer":{"id":8443,"kind":"organization","name":"Matinas BioPharma Holdings, Inc."},"owners":[{"id":96124,"kind":"person","name":"Kucinski Keith A","position":1,"cik":"0001763405","reported_name":"Kucinski Keith A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-01-04T23:30:10.000Z","date":"2021-01-01","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on January 1, 2022 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on February 1, 2022."}],"balance_after":500000,"derivative":{"exercise_price":1.36,"expiration_date":"2030-12-31","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001493152-21-000132","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582554/000149315221000132/ownership.xml","form_type":"4"}}],"next_cursor":"2021-01-04T23:30:10.000000Z,2924947"}